TITLE

Legislation may offer long-term solution

PUB. DATE
April 2011
SOURCE
Same-Day Surgery;Apr2011, Vol. 35 Issue 4, p35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on potential solutions to a growing drug shortage in the U.S. that were discussed at a 2010 drug summit which was sponsored by the American Society of Health-System Pharmacists and other groups and discusses legislation called the Preserving Access to Life-Saving Medications Act, which was proposed by U.S. Senator Amy Klobuchar and U.S. Senator Bob Casey, and may provide a long-term solution to the drug shortage.
ACCESSION #
59699327

 

Related Articles

  • FDA published 2 new rules regarding INDs.  // AIDS Alert;Nov2009, Vol. 24 Issue 11, p130 

    No abstract available.

  • FDA is pulling some 500 Rxs off market.  // Chain Drug Review;3/14/2011, Vol. 33 Issue 5, p2 

    The article reports on the plan of the U.S. Food and Drug Administration to take out about 500 unapproved cold and allergy medications.

  • Break in the silence around FDAMA section 114.  // PharmacoEconomics & Outcomes News;7/23/2011, Issue 633, p2 

    The article reports on a need for more clarity and flexible interpretation from the U.S. Food and Drug Administration (FDA) regarding the use of Section 114 of the 1997 US FDA Modernisation Act (FDAMA).

  • Breakthrough Drugs Need a Break.  // BioWorld Today;4/2/2012, Vol. 23 Issue 63, p4 

    The article focuses on a proposed bill in the U.S. Senate which requires the Food and Drug Administration (FDA) to mentor sponsors developing breakthrough therapies.

  • Changes on horizon for hydrocodone drugs.  // Neurology Alert;Aug2012, Vol. 30 Issue 12, p2 

    The article focuses on the FDA Safety and Innovation Act (S 3187), which provides a classification for all hydrocodone-containing products from Schedule III to Schedule II.

  • FDA to Review Regulations.  // BioWorld Today;5/2/2011, Vol. 22 Issue 84, p3 

    The article reports that the U.S. Food and Drug Administration (FDA) is assessing regulations regarding innovations.

  • WIN! Darvon, Darvocet Taken off Market. Blair, Bridgette // Public Citizen News;Jan2011, Vol. 31 Issue 1, p1 

    The article reports on the call for the U.S. Food and Drug Administration (FDA) to ban the painkiller propoxyphene or Darvon and its version acetaminophen or Darvocet. FDA contends that products containing propoxyphene will be taken off the market due to their harmful effects to heart rhythm...

  • Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. Stubbings, JoAnn; Joshi, Rutu A.; Hoffman, James M. // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1547 

    In this article the authors discuss the aspects of Risk Evaluation and Mitigation Strategy program (REMS) of the U.S. Food and Drug Administration (FDA). They present information on development, function and organizational structure of REMS. They also discuss the effect of REMS on pharmaceutical...

  • Regulatory watch: FDA PDUFA goals missed. Hay, Michael // Nature Reviews Drug Discovery;Jan2009, Vol. 8 Issue 1, p10 

    The article provides information on the U.S. Food and Drug Administration Amendments Act's (FDAAA) performance goal for its Prescription Drug User Fee Act (PDUFA). It discusses problems faced by the FDA in attaining its PDUFA performance goal such as being understaffed. A review of instances in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics